RxDoctor Payments Data

David Feist, PA

Medical · Watertown, SDNPI 1003243437

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,763 of the $6,379 with a category attached, or 74.7%. 19 manufacturers reported payments, led by Dermavant Sciences, Inc. at 34.4% of the total. Reporting peaked in 2023 at $2,272 and has fallen 94.0% since, to $136 in 2025. Among medical clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,379in general payments, 2019–2025

Across 189 payments — averaging $33.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dermavant Sciences, Inc.$2K
  • LEO Pharma Inc.$1K
  • Amgen$590
  • AbbVie$542
  • Incyte Corporation$297
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$253
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$1,54324%
  • Food & beverage$4,76375%
  • Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,379 in reported general payments places this provider in the 95th percentile of 43 medical providers in South Dakota.

See all medical providers in South Dakota

Medicare billing

Part B allowed, 2024
$93,858
Medicare patients
645
Services billed
2,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast16$94,741
Clobetasol Propionate122$7,687
Fluocinonide79$3,774
Clindamycin Phosphate48$2,057
Ketoconazole73$1,547
Triamcinolone Acetonide103$1,413
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc45$1,347
Tretinoin13$1,234
Metronidazole25$961
Econazole Nitrate12$415
Levocetirizine Dihydrochloride25$333
Doxycycline Hyclate14$244
Hydrocortisone43$198
Clotrimazole13$190
Mupirocin24$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$590$94,74116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 medical providers in South Dakota.

Other medical in Watertown

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →